Advertisement


Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes (French Language)

2016 ASCO Annual Meeting

Advertisement

Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses in French patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). 

 To see the English language version of this video, please click here.



Related Videos

Cost of Care
Issues in Oncology

Yousuf Zafar, MD, on the Financial Burden of Cancer Care

Yousuf Zafar, MD, of Duke Cancer Institute, summarizes his educational lecture on the financial toxicities of treatment and the need to focus on both short- and long-term interventions to reduce the burden on patients.

Neuroendocrine Tumors

Heinz-Josef Lenz, MD, and Jonathan R. Strosberg, MD, on the NETTER-1 Trial for Midgut Neuroendocrine Tumors

Heinz-Josef Lenz, MD, of the University of Southern California, and Jonathan R. Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discuss efficacy and safety results in patients with midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 4005).

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Gideon Michael Blumenthal, MD, of the US Food and Drug Administration, discuss milestone analyses with immune checkpoint inhibitors, targeted therapy, and standard therapy in metastatic non–small cell lung cancer trials submitted to the FDA (Abstract 9010).

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Heather A. Wakelee, MD, on Bevacizumab for Early-Stage NSCLC

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Heather A. Wakelee, MD, of Stanford University, discuss findings on adjuvant chemotherapy with or without bevacizumab for early-stage non–small cell lung cancer, with outcomes based on chemotherapy subsets (Abstract 8507).

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Michael A. Postow, MD, on Results From the CheckMate 067 Melanoma Trial

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discuss findings from this phase III trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced disease (Abstract 9505).

Advertisement

Advertisement




Advertisement